

**CORRECTION** **OPEN**

Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction

ChangDong Lin, Yue Li, YueBin Zhang , ZhaoYuan Liu, Xia Mu, Chenjian Gu, Jing Liu, Yutang Li, GuoHui Li and JianFeng Chen

Signal Transduction and Targeted Therapy (2021)6:230; <https://doi.org/10.1038/s41392-021-00643-y>

Correction to: *Signal Transduction and Targeted Therapy* <https://doi.org/10.1038/s41392-021-00619-y>, published online 18 May 2021

After online publication of the article¹ we noticed an error in citations for affiliation in the supplementary materials published in this article.

The citations for affiliation in the article were reordered during the production process to match the order of authors in the author group. Unfortunately, this was not reflected in the supplementary material.

We regret for not processing the revised supplementary material during the production process. Corrected supplementary material is published with this correction note.

The original article has been corrected.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41392-021-00643-y>.

REFERENCE

1. Lin, C., Li, Y. & Zhang, Y. et al. Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction. *Sig Transduct Target Ther* **6**, 198 (2021).



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021